The pharma company said it believes there’s plenty of room for multiple industry players in the obesity drug market.

Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy ...

CVS Health is exploring options that could include a breakup of the company to separate its retail and insurance units ...

SHOPPING: Achieve your weight loss goals without spending a fortune on FDA-cleared, compounded versions of popular GLP-1 ...

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...

Fueled by the rise of the blockbuster GLP-1 drugs, including Ozempic and Wegovy, thinness appears to be making a comeback in ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

A series of state and federal lawsuits challenging coverage exclusions for obesity drugs and procedures are testing the ...

Should you, would you, take Ozempic? It's a question I'm asked by friends and it's a hot topic among my scientist colleagues, ...

Big Joe Henry is managing his cravings and eating healthier with Jersey Weight Loss Clinic, so he's not worried about extra ...

Results of a recent study found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk ...